The senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about new opportunities for research into brain lesions and microglia.
Daniel Reich, MD, PhD
Advertisement
Articles by Daniel Reich, MD, PhD
The senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about further research his lab is conducting into MS mechanisms.
Understanding Mechanisms of MS Chronic Inflammation: Jemima Akinsanya, DO, and Daniel Reich, MD, PhD
The duo from the National Institutes of Health discussed how monitoring and treating paramagnetic rim lesions can improve patient care in multiple sclerosis.
The duo from the National Institutes of Health discussed the advantages of the ultra-high resolution imaging technology in research.
The senior investigator at the National Institutes of Neurological Disorders and Stroke outlined studies on anakinra and tolebrutinib as part of a new phase 2a clinical trial paradigm.
The senior investigator at the National Institutes of Neurological Disorders and Stroke discussed 2 treatments currently being evaluated for use in multiple sclerosis.
Advertisement
Latest Updated Articles
Finding New Therapeutic Targets in MS: Daniel Reich, MD, PhDPublished: April 14th 2021 | Updated:
- Microglia’s Role in MS and Other Neurodegenerative Diseases: Daniel Reich, MD, PhD
Published: April 27th 2021 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Why Subtype Matters: Genetic Testing, Registries, and the Road to LGMD Treatments
2
LGMD Awareness Day: A Researcher’s Perspective on Rare Disease Progress and Gaps
3
Adipose-Derived Mesenchymal Stem Cell Therapy Meets Primary End Point in Phase 2 Trial of Relapsing-Remitting MS
4
Early Use and Duration of B-Cell Therapies in Multiple Sclerosis
5
